We proposed to study the nature and regulation of effector cells and target antigens in patients with graft-versus-host disease (GVHD). These studies will extend previous project work which demonstrated GVHD-associated populations of cytotoxic, proliferative, and specific and nonspecific suppressor cells in the peripheral blood of patients with acute and chronic GVHD, respectively. The main hypotheses to be tested in this project are as follows: A. A subpopulation of donor T cells can specifically bind and respond to recipient epidermal cells. B. Cellular cytotoxicity in cutaneous acute GVHD is mediated by cytotoxic T lymphocytes (CTL) as opposed to other CD8+ cytotoxic effector cells. These CTL recognize target antigens in the context of host HLA products, i.e., they are HLA-restricted. C. Skin cells secrete cytokines (IL1 and tissue growth factors) that stimulate lymphoid effector cell function and secretion of cytokines. These lymphoid cytokines (e.g., gamma interferon and colony stimulating factors) complete an inflammatory circuit by amplifying skin cytokine secretion and target antigen expression. Our approach will involve the culture of skin explants and skin components from pre- and post marrow transplant patient biopsies. Putative effector cells will be expanded from the latter biopsies, from patient peripheral blood, and from bone marrow. These cell populations will then be combined in vitro to analyze effector/target binding specificity and function, and to study the roles of lymphokines and tissue growth factors in these interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018221-12
Application #
3938040
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mielcarek, Marco; Storer, Barry E; Boeckh, Michael et al. (2009) Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113:2888-94
Tseng, Li-Hui; Storer, Barry; Petersdorf, Effie et al. (2009) IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation 87:704-10
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Storek, Jan (2008) Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Expert Opin Biol Ther 8:583-97
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Carpenter, Paul A; Hoffmeister, Paul; Chesnut 3rd, Charles H et al. (2007) Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant 13:683-90
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Alkindi, S; Deeg, J H; Flowers, M E D (2006) Recovery of normal autologous myelopoiesis after graft rejection following allogeneic bone marrow transplant for agnogenic myeloid metaplasia. Clin Lab Haematol 28:134-7

Showing the most recent 10 out of 692 publications